Sino Biopharmaceutical Limited (HKEX:1177) Annual Report 2021



The latest annual report of Sino Biopharmaceutical Limited (1177) was published on 31 Dec 2021. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - 1177 Annual Results

Amounts in CNY

Total Revenue
26.86B
Gross Profit
21.53B
EBIT
4.23B
Net Tangible Assets
29.35B
Net Income
14.61B
Capital Expenditures
-1.71B

1177 Income Statement 2021 Annual Report

As per the latest Income Statement of 1177, the Net revenue increased by ¥3.214132B (14%) compared to the previous period. The operating income in 2021 increased by ¥130.40M (3%). The net income as per the annual report was 14.61B which increased by ¥11.837326B (427%) compared to previous year.

Income Statement Report (2021/2020)

2021 2020
Total Revenue 26.86B 23.65B
Gross Profit 21.53B 18.46B
Operating Income 4.23B 4.1B
Income Before Tax 18.57B 5.01B
Net Income 14.61B 2.77B

Balance Sheet - 1177 2021 Annual Report

Read further: 1177 Balance Sheet Detailed Analysis

The latest balance sheet from annual result of Sino Biopharmaceutical Limited showed the company reduced the cash on balance sheet by ¥-690.27M (-6%). The Net tangible assets of 1177 on the balance sheet were at 29.35B which is ¥12.918742B (79%) more than previous annual report. The total stockholder equity also increased by ¥13.543956B (81%) compared to previous reporting period.

Balance Sheet Statement Report (2021/2020)

2021 2020
Cash 10.57B 11.26B
Total Assets 60.54B 47.21B
Long Term Debt 5.21B 12.36B
Total Liabilities 22.81B 24.79B
Total Shareholder Equity 30.29B 16.75B
Net Tangible Assets 29.35B 16.43B

Cash Flow Statement - 1177 2021 Annual Report

The 2021 annual cash flow statement of Sino Biopharmaceutical Limited showed that the net income increased by ¥11.837326B (427%) compared to previous reporting period. Also the capital expenditure of 1177 decreased by ¥-289.84M (-20%).

As of 2021, the total cash from investing activities was -2.52B and total cash from financing activities was -3.23B.

Cash Flow Statement Report (2021/2020)

2021 2020
Net Income 14.61B 2.77B
Capital Expenditures -1.71B -1.42B
Dividends Paid -938.49M -1.19B
Total Cash From From Investing Activities -2.52B -7.85B
Total Cash From From Financing Activities -3.23B 2.23B

Sino Biopharmaceutical Limited Annual Report History

Income Statement

Income Statement history of Sino Biopharmaceutical Limited (HKEX:1177)

31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Total Revenue 26.86B 23.65B 24.23B 20.89B
Cost Of Revenue 5.33B 5.18B 4.93B 4.2B
Gross Profit 21.53B 18.46B 19.31B 16.69B
Research Development - - - -
Selling General Administrative 12.7B 11.63B 11.8B 10.27B
Non Recurring - - - -
Other Operating Expenses 4.6B 2.74B 2.56B 2.3B
Total Operating Expenses 22.63B 19.55B 19.28B 16.77B
Operating Income 4.23B 4.1B 4.95B 4.12B
Total Other Income Expense Net 14.34B 914.62M 737.54M 7.31B
Ebit 4.23B 4.1B 4.95B 4.12B
Interest Expense -308.62M -323.37M -229.95M -153.26M
Income Before Tax 18.57B 5.01B 5.69B 11.43B
Income Tax Expense 1.96B 672.38M 902.75M 696.24M
Minority Interest 7.44B 5.67B 5.61B 8.34B
Net Income From Continuing Ops 16.61B 4.34B 4.79B 10.73B
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Charges - - - -
Other Items - - - -
Net Income 14.61B 2.77B 2.76B 9.05B
Net Income Applicable To Common Shares 14.61B 2.77B 2.76B 9.05B

Balance Sheet Statement

Balance Sheet Statement history of Sino Biopharmaceutical Limited (HKEX:1177)

31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Cash 10.57B 11.26B 11.91B 6.68B
Short Term Investments 569.5M 956.01M 5.62B 4.35B
Net Receivables 5.54B 4.08B 3.34B 3.87B
Inventory 1.94B 1.88B 1.66B 1.21B
Total Current Assets 23.5B 22.79B 24.91B 18.54B
Long Term Investments 25.17B 13.86B 2.02B 1.07B
Property Plant Equipment 8.52B 8.39B 7.63B 5.8B
Good Will 647.93M 88.93M 88.93M 13.9B
Intangible Assets 291.56M 225.35M 821.06M 7.84B
Other Assets 2.42B 1.85B 2.04B 2.63B
Deferred Long Term Asset Charges 334.87M 463.37M 557.35M 470.56M
Total Assets 60.54B 47.21B 37.51B 49.78B
Accounts Payable 1.79B 1.95B 1.81B 1.83B
Short Long Term Debt 6.52B 1.55B 22.13M 48.11M
Other Current Liab 1.68B 3.22B 2.06B 1.68B
Long Term Debt 5.21B 12.36B 7.88B 507.07M
Other Liab 1.94B 1.22B 903.91M 2.05B
Deferred Long Term Liab 772.46M 699.36M 503.15M 504.98M
Minority Interest 7.44B 5.67B 5.61B 8.34B
Total Current Liabilities 15.35B 10.94B 8.12B 9.67B
Total Liab 22.81B 24.79B 16.95B 12.23B
Common Stock 415.44M 415.89M 278.45M 278.85M
Retained Earnings 27.21B 13.6B 11.95B 16.81B
Treasury Stock -9.92B -9.96B -10.25B -920.14M
Capital Surplus 12.58B 12.69B 12.97B 13.04B
Other Stockholder Equity -9.23B -9.49B -9.83B -462.85M
Total Stockholder Equity 30.29B 16.75B 14.95B 29.21B
Net Tangible Assets 29.35B 16.43B 14.04B 7.47B

Cash Flow Statement

Cash Flow Statement history of Sino Biopharmaceutical Limited (HKEX:1177)

31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Net Income 14.61B 2.77B 2.76B 9.05B
Depreciation 922.74M 1.64B 1.4B 1.16B
Change To Netincome -9.96B 568.8M 1.36B -5.42B
Change To Account Receivables -1.31B -198.79M 196.31M -436.21M
Change To Liabilities -191.59M 334.05M -143.2M 870.48M
Change To Inventory -57.48M -221.45M -449.44M -102.16M
Change To Operating Activities 1.22B 347.52M 113.52M -88.81M
Total Cash From Operating Activities 5.37B 5.33B 5.32B 5.09B
Capital Expenditures -1.71B -1.42B -1.45B -1.55B
Investments -4.39B -6.54B -2.45B -668.25M
Other Cashflows From Investing Activities 4.41B 383.13M 343.89M 510.46M
Total Cashflows From Investing Activities -2.52B -7.85B -3.82B -616.1M
Dividends Paid -938.49M -1.19B -819.69M -710.33M
Net Borrowings -1.5B 5.34B 5.17B 304.67M
Other Cashflows From Financing Activities -452.37M -1.72B -1.51B -1.17B
Total Cash From Financing Activities -3.23B 2.23B 2.8B -2.18B
Effect Of Exchange Rate -649.71M 280.01M 95.05M 242.47M
Change In Cash -1.02B -7.02M 4.4B 2.54B
Repurchase Of Stock -332.93M -195.37M -32.05M -604.42M